These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2364 related articles for article (PubMed ID: 16214252)

  • 21. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
    Gherardi MM; Ramírez JC; Esteban M
    J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance of CD8(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses.
    Villacres MC; Zuo J; Bergmann CC
    Virology; 2000 Apr; 270(1):54-64. PubMed ID: 10772979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
    Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
    Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W; Li S; Hu Y; Tang B; Cui L; He W
    Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
    Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
    Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
    Bolesta E; Kowalczyk A; Wierzbicki A; Eppolito C; Kaneko Y; Takiguchi M; Stamatatos L; Shrikant PA; Kozbor D
    J Immunol; 2006 Jul; 177(1):177-91. PubMed ID: 16785513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
    Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
    J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
    Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B.
    Rodríguez AM; Turk G; Pascutti MF; Ferrer F; Nájera JL; Mónaco D; Esteban M; Salomón H; Calamante G; Gherardi MM
    Virus Res; 2009 Dec; 146(1-2):1-12. PubMed ID: 19715734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    Akahata W; Yang ZY; Nabel GJ
    J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
    Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.
    Burgers WA; Shephard E; Monroe JE; Greenhalgh T; Binder A; Hurter E; Van Harmelen JH; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):195-206. PubMed ID: 18240957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
    Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
    Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 119.